Short answer
Oruka Therapeutics, Inc. (ORKA) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$30M
- +43.1% YoY · −23.2% QoQ
Source: XBRL data from the Oruka Therapeutics, Inc. (ORKA) Q3 2025 10-Q on SEC EDGAR. USD.
Oruka Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: At-the-market equity offering program up to $200M initiated in Oct 2025 to raise capital amid market volatility and regulatory uncertainty
- Updated risk: Clinical trial delays and potential increased costs highlighted due to slow enrollment and third-party contractor noncompliance risks
- Regulatory risk: Dependence on regulatory approvals for drug-device combinations with possible delays from complex review processes and device supplier issues
- Market risk: Intensified competition from larger biopharma firms and biosimilars impacting enrollment and market penetration for ORKA-001 and ORKA-002
- Financial risk: Recent capital raises including 10.9M common shares in Sep 2025 caused shareholder dilution; ongoing need for substantial funding to continue operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oruka Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.